Electronic skin patches represent one wearable technology product type that is well suited for physiological monitoring. Placing a connected electronic device onto the skin via an adhesive provides a platform that can house many different kinds of sensors, most prominently for medical monitoring of the wearer.
Over the last 18 months, the COVID-19 pandemic has driven a concerted worldwide effort to explore and revise our patient monitoring and infectious disease management approaches. As with other wearable devices, electronic skin patch products have evolved significantly over this period.
The impact of COVID-19 has been significant for many sectors but in vastly different ways. Products for remote patient monitoring saw a substantial increase in demand and deployment, with remote monitoring options being significantly more favourable when dealing with a highly infectious disease. Regulatory hurdles were lowered to meet the emergency demand during the pandemic, which saw many companies accelerate their commercialisation on existing paths. This particularly helped companies in the early stage of commercialisation get to the next step of scale-up in the long journey to commercialise a mainstream medical device.
For many other sectors, the changes were more subtle. As with other markets, local lockdowns impacted products that require in-person delivery, such as a visit to a cardiologist. However, with many companies already trialling telehealth options, they were often quickly able to scale these up to enable remote delivery of products. As such, whilst late Q1 and Q2 figures may have been impacted negatively, many companies recovered exceptionally quickly and facilitated shifts to potentially more profitable models involving tools such as telehealth.
The net result is that many trends observed in the electronic skin patch market have been accelerated. Familiarity with telehealth and its general acceptance has seen a notable increase in uptake. Remote patient monitoring options have developed further, not just within the monitoring and treatment of specific disease verticals but also in more general settings. Both of these have been underpinned by a series of prominent acquisitions, seeing some major medical device companies acquiring leading skin patch companies to integrate them within broader digital healthcare ecosystems. Philips' acquisition of BioTelemetry for $2.8bn, announced in December 2020, is the largest and most significant and one of several deals covered and discussed in IDTechEx's latest report on the topic, "Electronic Skin Patches 2021-2031".
This report describes each of the key market sectors where electronic skin patch products are used today. As a diverse product platform, these markets have unique dynamics and product ecosystems in which skin patches play a particular role. However, there are also many overarching themes in both technology and business model which span the product sector. The report covers each of these in turn, with historical data back to 2010 and market forecasts to 2031 for each sector covered. As part of this narrative, activities of over 130 companies are covered, including over 50 interviews by IDTechEx analysts as part of the team's focus on primary research.
More Great Dubai Route Stories
Beat the Heat This Summer With Dubai’s Tastiest Desserts
VMware Certifies the BenQ DuoBoard for Optimized Integration and Interoperability
Ideal Standard MENA Partners With the Belgian Pavilion at Expo 2020 Dubai
DP World Kickstarts 2021 on a High Note With Projects in Varied Crucial Sectors
Dubai Police Makes 9-Year-Old’s Dream Come True With the Help of Voices of Future Generations.
DISCLAIMER
Global Business, Financial News, Market Data, and Analysis published here are delayed 24 hours. All the published information, analyses and conclusions are based (unless sourced otherwise) on external information and Dubai Route Group’s experts' judgment. They are intended as guides only and should not be construed as definitive forecasts or guarantees of future performance or results. No responsibility or liability is accepted by any person, including Dubai Route Group or its affiliates and their respective officers, employees or agents, for any errors or omissions.